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Background 
There have been reports that corticosteroids, used in 
addition to antituberculous therapy, may benefit people 
with tuberculous pleurisy. However, research findings 
are inconsistent, and there are potential adverse effects 
of corticosteroids, especially in HIV-positive people. 
Inclusion criteria 
Studies:  
Randomized controlled trials and quasi-randomized 
controlled trials. 
Participants: 
People diagnosed with tuberculous pleurisy.  
Intervention: 
Intervention: any corticosteroid. 
Control: no treatment, placebo or other active treatment. 
Selected outcomes: 
Death from any cause, improvement in respiratory 
function, reabsorption of clinical effusion, presence of 
plural thickening, improvement in clinical symptoms 
and signs, HIV-associated events.  
Results 
• Six trials comprising 633 participants were included; 
one trial had adequate allocation concealment. 
• One trial found that corticosteroids had no significant 
effect on the number of deaths (194 participants). 
• There was no significant improvement in respiratory 
function in those taking corticosteroids compared with 
control (191 participants, 2 trials). 
• Presence of residual fluid at four weeks (relative risk 
0.76, 95% confidence interval 0.62 to 0.94; 394 
participants, 3 trials) and pleural thickening (RR 0.69, 
95% CI 0.51 to 0.94; 309 participants, 4 trials) were 
lower in participants receiving corticosteroids. 
Presence of residual fluid at eight weeks was no 
different in the corticosteroid group compared with 
controls (399 participants, 4 trials). 
• Symptoms disappeared faster in people receiving 
corticosteroids (weighted mean difference -4.32 days, 
95% CI -7.44 to -1.20; 123 participants, 2 trials). 
• Adverse events leading to treatment discontinuation 
were more common among those taking 
corticosteroids (RR 2.80, 95% CI 1.12 to 6.98; 586 
participants, 6 trials). 
• One trial showed the risk of Kaposi’s sarcoma may be 
increased in HIV-positive people taking corticosteroids 
(194 participants). 
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Do corticosteroids prevent death and improve respiratory function 
in people with tuberculous pleurisy? 
There is insufficient evidence to determine whether corticosteroids 
benefit people with tuberculous pleurisy. 
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Authors’ conclusions 
Implications for practice:  
There is insufficient evidence to determine whether potential benefits of corticosteroids outweigh potential harms 
for people with tuberculous pleurisy.  
Implications for research: 
Further large trials with sufficient statistical power to evaluate the effects of corticosteroids on mortality and 
important morbidity outcomes are needed. Careful attention should be given to adverse events, particularly in HIV-
positive people. 
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